The DOI matches its Crossref record; 130 of the 140 references it cites were found in a registry or an index.
COVID-19 cytokine storm: The anger of inflammation
Open accessAbstract
Patients with COVID-19 who require ICU admission might have the cytokine storm. It is a state of out-of-control release of a variety of inflammatory cytokines. The molecular mechanism of the cytokine storm has not been explored extensively yet. The attachment of SARS-CoV-2 spike glycoprotein with angiotensin-converting enzyme 2 (ACE2), as its cellular receptor, triggers complex molecular events that leads to hyperinflammation. Four molecular axes that may be involved in SARS-CoV-2 driven inflammatory cytokine overproduction are addressed in this work. The virus-mediated down-regulation of ACE2 causes a burst of inflammatory cytokine release through dysregulation of the renin-angiotensin-aldosterone system (ACE/angiotensin II/AT1R axis), attenuation of Mas receptor (ACE2/MasR axis), increased activation of [des-Arg9]-bradykinin (ACE2/bradykinin B1R/DABK axis), and activation of the complement system including C5a and C5b-9 components. The molecular clarification of these axes will elucidate an array of therapeutic strategies to confront the cytokine storm in order to prevent and treat COVID-19 associated acute respiratory distress syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among them, IL-6 is a major player in chronic inflammatory diseases, autoimmune diseases, cancer and cytokine storm (1, 3, 10–26).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, SARS-CoV-1 and SARS-CoV-2 infection activate both NF-κB and STAT3, key elements of the IL-6 Amp, to cause cytokine storm (12, 13, 15, 349, 350).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ARDS in COVID-19 is considered the result of cytokine storm (12–17), resembling the disease caused by SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV) (335).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Consistent with the notion that severe COVID-19 is a cytokine storm syndrome (12–17, 336), the severity of COVID-19 is associated with an increased level of inflammatory cytokines, such as IL-6, granulocyte macrophage colony-stimulating factor (GM-CSF) and TNFα (333, 337).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545 · cited 9×
“An increment of the highly pro-inflammatory CCR6+ Th17 in CD4 T cells was reported in COVID-19 associated with ARDS [9].”
InfluentialStructure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983 · cited 3×
“These severe cases that develop respiratory failure show a series of pathological findings such as hyaline membrane formation, inflammatory infiltration with multinucleated syncytial cells in their lung pathology and a burst of cytokine release leading to morbidity and mortality [6,12].”
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study
Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., et al. (2020) · BMJ · doi:10.1136/bmj.m1091 · Cited by 3,903
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453 · cited 1×
“The protective effect of ACE2 in severe acute lung failure has been shown in animal models [40].”
Ziegler, C. G. K., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., Cao, Y., Yousif, A. S., Bals, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.035 · Cited by 2,284 · cited 2×
“ACE2 enzyme is expressed in the heart, kidneys, testes, gastrointestinal tract and lungs [15,31].”
MAGRO, C. M. J., Mulvey, J. J., Berlin, D., Nuovo, G. J., Salvatore, S., Harp, J., Baxter-Stoltzfus, A., & Laurence, J. C. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.007 · Cited by 2,224 · cited 1×
“[112] reported a pauci-inflammatory changes and lack of viral cytopathic effects accompanied with heavy deposition of C5b-9, C4d and MBL-MASP2 in lung septal vasculatures of 5 patients with”
Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado del Pozo, C., Prosper, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.004 · Cited by 2,122
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Research works printed but not linked: 3
- Bm, 2020, COVID-19 induced Renin-Angiotensin System (RAS) imbalance may drive acute lung injury: the evidence and therapeutic options, BMJ, 368
- Gheblawi, 2020, Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System, Circ. Res.
- Gao, 2020, Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation, medRxiv
Cited by
Sorted by citations
Items 401–459 of 459
Vitamin D Reduces Covid-19 Mortality and Serious Illness: An Integrated Approach to EvidencePreprint
King, E. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/95jsd
Una formulación de orden fraccionario de un modelo simplificado de la dinámica de citoquinas
González-Ramírez, L. R. (2022) · PÄDI Boletín Científico de Ciencias Básicas e Ingenierías del ICBI · doi:10.29057/icbi.v10iespecial.8529
Qu, W., Wang, Z., Engelberg-Cook, E., Siddik, A. B., Bu, G., Allickson, J. G., Kubrova, E., Caplan, A. I., Hare, J. M., Ricordi, C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3924851
Rattis, B. A. D. C. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2022.tde-13072022-152534
Comprehensive Review of COVID-19 on Benign Prostate Hyperplasia Patient Symptoms
Choi, J., Suh, H. J., Lee, D. H., Hwang, T., & Kim, J. J. (2022) · Urogenital Tract Infection · doi:10.14777/uti.2022.17.2.31
Sierra, J. A., Astorga, C. D., Nava-Vargas, M. G., Campos, E. R., Arellano-Arteaga, K. J., Hernández-Morales, K., Andrade-Castellanos, C. A., de Jesús, A.-O. A., & Gonzalez-Correa, L. G. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/1363994
Paiva, D. F. F. (2022) · Revista Ciência Plural · doi:10.21680/2446-7286.2022v8n3id27644
“Tocilizumab Impede a ação da IL-6 Receptor da IL-6 sgp130Fc-anti-CD16 Bloqueia a proteína S Proteína viral do SARSCoV-2 Eberli et al, 2020(13) Tocilizumab Inibe a ação da IL-6 Receptor da IL-6 Sarilumab Inibe a ação da IL-6 Receptor da IL-6 Mahmudpour et al, 2020(14) Eculizumab Evita a clivagem do C5 em C5a e C5b Sist…”
BackgroundInfluentialModel exploration for discovering COVID-19 targeted traditional Chinese medicine
Sun, Y., An, X., Jin, D., Duan, L., Zhang, Y., Yang, C., Duan, Y., Zhou, R., Zhao, Y., Zhang, Y., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12333
“After SARS-CoV-2 infection, the expression of p38 MAPK, NF-kB, IL-6, IL-8, and other in fl ammatory factors changes [99].”
Valverde, R. G. (2022) · Miscelánea A Journal of English and American Studies · doi:10.26754/ojs_misc/mj.20227360
Covid-19: monitoring of patients’ laboratory data during a 90-day length of hospital stay
Perraud, E. B. D. C., Oliveira, B. D. D., Meireles, L. S. M. D. A., Moreira, T. B. M., Loureiro, V. L., Rocha, H. A. L., & Martins, F. P. R. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n6-169
“Therefore, the need for serial measurements of inflammatory and thrombotic markers when monitoring the disease evolution would be justified [18].”
BackgroundAgarwal, R., Atreyapurapu, V., Sharma, P., Yerramsetty, V. K., Saripalli, C., Reddy, K. S., Atturu, G., & Gupta, P. C. (2022) · Indian Journal of Vascular and Endovascular Surgery · doi:10.4103/ijves.ijves_47_22
KIM, Y. T., Nguyen, T. T., Duong, D. N., Nguyen, T. T. N., & Tran, H. V. (2022) · Science and Technology Development Journal - Natural Sciences · doi:10.32508/stdjns.v6i4.1169
Inflammatory environment in patients with COVID-19
Ventura, I. (2023) · Nereis Interdisciplinary Ibero-American Journal of Methods Modelling and Simulation · doi:10.46583/nereis_2022.1.1036
Morphological aspect of the angiotensin-converting enzyme 2
Yoshimura, K., Okada, Y., Toya, S., Asami, T., & Iwasaki, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99618-1.00008-8
Delgado, A. C., Cornett, B., Choi, Y. J., Colosimo, C. M., Stahel, V. P., Dziadkowiec, O., & Stahel, P. F. (2023) · Patient Safety in Surgery · doi:10.1186/s13037-023-00358-9
Barbullushi, A., Kristo, A., Davidhi, A., & Kullolli, I. (2023) · International Journal of Biomedicine · doi:10.21103/article13(2)_cr5
Shkolnikova, M. N., Averyanova, E. V., & Рожнов, Е. Д. (2023) · Food Industry · doi:10.29141/2500-1922-2023-8-2-12
Reactivación y coinfecciones virales en COVID-19: otro elemento a considerar. Revisión Sistemática
Pincay, R. A. P., & Diana Callejas, M. (2023) · Kasmera · doi:10.56903/kasmera.5138571
Watelo, A. K., Ankunda, V., Ssali, I., Oluka, G. K., Mugaba, S., Katende, J. S., Ejou, P., Auma, B. O., Nantambi, H., The COVID-19 Immuno-profiling Group, et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3558086/v1
Prolonged Air Leak After Pleurectomy/Decortication Surgery in Two Patients with COVID-19 Pneumonia
ŞATIR, M., Tombul, İ., Sayan, M., Çelik, A., & Taştepe, A. İ. (2023) · Phoenix Medical Journal · doi:10.38175/phnx.1231855
The CD147 Epitope on SARS CoV2 and the Spike in Cancer, Autoimmunity and Organ Fibrosis
(2023) · Medical & Clinical Research · doi:10.33140/mcr.07.051
Fu, C., Zhu, Y., Huang, W., Luo, Y., Hu, Y., Huang, H., & Sun, J. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s435160
Zbinden‐Foncea, H., Tapia‐Curimil, G., Díaz, A., Tuñón‐Suárez, M., Castro‐Sepúlveda, M., Fuentes, J., Marambio, H., Francaux, M., & Deldicque, L. (2024) · Advanced Exercise and Health Science · doi:10.1016/j.aehs.2024.01.001
Carnaúba, A. Q., de Omena, I. C., & Aquilino, G. M. D. A. (2024) · doi:10.22533/at.ed.0132412024
REAÇÃO ADVERSA IMEDIATA APÓS DOSE DE REFORÇO DA VACINA PFIZER CONTRA SARS-COV-2: UM RELATO DE CASO
Reis, F. L., Toniasso, S. D. C. C., Pereira, R. M., Baldin, C. P., Trindade, D. M., Joveleviths, D., & Brum, M. C. B. (2024) · doi:10.22533/at.ed.0132412026
SÍNDROME PÓS-COVID-19 E INTERVENÇÕES DIETÉTICAS PARA O TRATAMENTO DAS SEQUELAS
da Silva, D. K. M., dos Santos, R. A. L., Aguiar, M. M. L. S. D. A., & Gerônimo, A. M. M. (2024) · doi:10.22533/at.ed.0132412023
MUDANÇAS DE COMPORTAMENTO NOS TRANSTORNOS ALIMENTARES PÓS-COVID-19: UM PROBLEMA DE SAÚDE PÚBLICA
Dantas, A. L. A., da Silva, V. C. P., & Uchôa, P. D. A. (2024) · doi:10.22533/at.ed.0132412022
INSEGURANÇA ALIMENTAR E NUTRICIONAL NO BRASIL: IMPACTOS DA COVID-19 NA REGIÃO NORDESTE
Lins, G. C. M. S. M., Sátiro, Y. D. S., de Menezes, I. B. C., & Uchôa, P. D. A. (2024) · doi:10.22533/at.ed.0132412021
Resposta à COVID-19: ciência, sociedade e desafios globais
Cavalcanti, S. A. U. (2024) · doi:10.22533/at.ed.013241202
胡, 国. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.142515
Laudański, K., Mahmoud, M. A., Sayed, A., Susztak, K., Mathew, A., & Chen, J. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073714
Albabtain, M. S., Alyousef, K., Alharbi, Z. M., Almutairi, M. N., & Jawdat, D. M. (2024) · Cureus · doi:10.7759/cureus.59468
Complement is Primarily Activated in the Lung in a Severe COVID-19 Mouse ModelPreprint
Szachowicz, P. J., Wohlford-Lenane, C., Heinen, C. J., Ghimire, S., Xue, B., Boly, T. J., Verma, A., MašinoviĆ, L., Bermick, J., Perlman, S. M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4878210
Prolonged COVID-19's Double Impact: Stress and Male Fertility
Alkireidmi, M. A., Kaleem, M., Naqvi, S., Al-Abbasi, F. A., Kamal, M. A., & Anwar, F. (2024) · Coronaviruses · doi:10.2174/0126667975316497240725102111
Агеева, Е. С., Ablaeva, R. N., Rymarenko, N. V., Yatskov, I. A., Beloglazov, V. A., & Zhukova, A. A. (2024) · Russian Journal of Immunology · doi:10.46235/1028-7221-16742-fop
The treatment of COVID-19: lessons learned and future directions
Cenname, M., & McCarthy, M. W. (2024) · Future Virology · doi:10.1080/17460794.2024.2385871
Neves, P. F. R., Paz, L. V., Wieck, A., & Xavier, L. L. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111488
The Place of Mature Drugs in COVID-19 Era
Pasquali, C., Zingg, D., Ballarini, S., Rossi, G. A., & Haller, H. G. (2024) · Frontiers in clinical drug research. Anti-infectives/Frontiers in clinical drug research. Anti infectives · doi:10.2174/9789815179811123090003
Population-specific polymorphisms and SARS-CoV-2 infectivity
Jain, N., & Chatterjee, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00003-6
Ibraheem, A. A. A., Saleh, S. A., Emam, A. A., Yousef, A. A., Abdulhay, M., Haridi, M. K., Wahba, A. A., Al‐Fahham, M. M., Selim, D., Razek, S. A., et al. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.27479
“ACE2 is at the center of complex COVID ‐ 19 pathophysiological crossroads [33].”
Zverev, Y. F., & Rykunova, A. Y. (2024) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683824700194
“This contributes to the development of a syndrome called a cytokine storm [25, 28, 30, 31].”
Lower C3 and C4 Complement Serum Levels Are Associated with More Severe Forms of COVID-19 Disease
Čulo, M.-I., Marković, I., Šavuk, A., Zagorec, N., Kereš, T., Grizelj, D., Lisičić, A., Bušić, N., Šakota, S., Kmet, M., et al. (2025) · Viral Immunology · doi:10.1177/08828245251362439
“…the severity and mortality of COVID-19 are associated with excessive activation of the in fl ammatory system, leading to increased levels of numerous cytokines and chemokines, hyperin fl ammation, and organ damage (Hojyo et al., 2020; Kim et al., 2020; Mahmudpour et al., 2020; Szabo et al., 2021).”
Mine, Y., Wei, T., & Tu, Y. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24738-5.00006-9
Li, Y., Duche, A., Sayer, M. R., Roosan, D., Khalafalla, F. G., Ostrom, R. S., Totonchy, J. E., & Roosan, M. R. (2021) · Figshare · doi:10.6084/m9.figshare.14059936
Fan, Y., Wang, Y., Yu, S., Chang, J., Yan, Y., Wang, Y., & Bian, Y. (2021) · Figshare · doi:10.6084/m9.figshare.15071437
de Lara, J. D., Vidal, T., de Souza, J. B., Kodavara, E., Decker, E. R., Grotto, F. S., Bortoluzzi, L. D., dos Santos, A. P. S., Brusco, I., Oliveira, S. M., et al. (2025) · Immunology Letters · doi:10.1016/j.imlet.2025.107125
Öztürk, T., Çavuşoğlu, T., İncir, C., & Tunçok, Y. (2021) · DergiPark (Istanbul University)
Nath, D., Noman, A. A., Pradhan, S., Sharma, P., Ahmed, S., Begum, F., Hafiz, M. A., & Abdallah, E. M. (2026) · 3 Biotech · doi:10.1007/s13205-026-04749-4
Guo, Y., Qi, Y., Zhou, F., Zhou, M., Li, X., Wang, Y., Chen, Y., & Ding, Z. (2026) · European journal of medical research · doi:10.1186/s40001-026-04067-8
Barbosa, C. L. N., Porto, S. L. T., Pereira, R. D. D., Oliveira, N. F. D. M., Ricci, M. F., Rabelo, R. A. N., Leite, P. G., Oliveira, F. B. R., REZENDE, I. C., Souza, J. L. N., et al. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108457
Wu, W., Rippee‐Brooks, M. D., Adam, A., Weinstein, K. H., Ola-Daniel, F., Zhang, K., Choi, E., Deepak, D., Vega, J., Ishimwe, K., et al. (2026) · Journal of Medical Virology · doi:10.1002/jmv.70881
Sadiq, A. A. (2022) · theses.fr (ABES) · doi:10.70675/48c36f30za7acz41d9z9bc3zc112ba09c027 · Cited by 2
Ghimire, B., Giri, P., Tavernier, S. S., Hobdey, S. E., & Aghazadeh‐Habashi, A. (2026) · Biomedicines · doi:10.3390/biomedicines14051086
“This overactivation activates nuclear factor kappa B (NF-κ B) and MAPK signaling, which drive the secretion of inflammatory cytokines such as IL-1, IL-6, and TNF-α , further augmenting the inflammatory process [26,27].”
Deciphering the role of angiotensin converting enzyme2 in health and diseases
Sivasakthivel, S., & Ramani, P. (2026) · RUDN Journal of Medicine · doi:10.22363/2313-0245-2025-30-2-177-199
Teerawattanapong, N., Chaimaha, G., Narkdontri, T., Songlilitchuwong, S., Innang, S., Suthon, S., & Tangjittipokin, W. (2026) · Journal of Interferon & Cytokine Research · doi:10.1177/10799907261466763
“More severe COVID-19 characterization elevated innate immunity of in fl ammatory cytokines (e.g., IL6, IL1 b , and TNF a ) (Mahmudpour et al., 2020; Tang et al., 2021).”
Metadata
- Authors
- Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S., & Nabipour, I.
- Affiliations
- Bushehr University of Medical Sciences (IR)
- Shiraz University of Medical Sciences (IR)
- Iranian Academy of Medical Sciences (IR)
- Corresponding author
- Nabipour, Iraj
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 133
- Pages
- 155151
- ISSN
- 1043-4666 (ISSN-L)
- PMC
- PMC7260598
- OpenAlex
- W3030136428
- Cited by
- 461
- References
- 140
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 47 · 2023: 61 · 2022: 104 · 2021: 168 · 2020: 52
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cytokine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bushehr University of Medical Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- COVID-19 pandemic, cytokine storm, SARS-CoV-2, hyperinflammation, ACE2, renin-angiotensin-aldosterone system, Mas receptor, bradykinin B1 receptor, complement system, C5a, membrane attack complex, acute respiratory distress syndrome, intensive care unit patients, treatment options
- MeSH terms
- Betacoronavirus, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, Proto-Oncogene Mas, Bradykinin, Humans, Inflammation, Peptidyl-Dipeptidase A, Models, Molecular, Pneumonia, Viral, Proto-Oncogene Proteins, Renin-Angiotensin System, Complement C5a, Cytokines, Coronavirus Infections, Receptors, G-Protein-Coupled, Complement C5b, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
